Plinabulin

普那布林

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NamePlinabulin
Drug Alias NamePlinabuline普立布林普那布尔PlinabulinumPlinabulina +[8] 
ClassificationNatural product/ExtractSmall molecules > Heterocyclic drugs
Mechanisms of ActionRho guanine nucleotide exchange factor 2 agonistsTubulin inhibitorsAntigen-presenting cells stimulants
TargetsRho guanine nucleotide exchange factor 2TubulinAntigen-presenting cells
Therapy Area/IndicationsSkin MelanomaSolid tumoursChemotherapy-Induced Febrile Neutropenia +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUkraineRussian Federation +[9] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesNereus Pharmaceuticals Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesPharmaceutics International, Inc. (Pii)BeyondSpring Pharmaceuticals IncDalian Wanchun Biotechnology Co Ltd
Inactive CompaniesNereus Pharmaceuticals IncDalian Wanchun Bulin Pharmaceutical Co LtdThe University Of Texas MD Anderson Cancer Center +[4] 
Active IndicationsNeutropeniaSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[5] 
Inactive IndicationsSkin MelanomaSolid tumoursChemotherapy-Induced Febrile Neutropenia +[8] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG